Status:
UNKNOWN
Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies
Lead Sponsor:
Ospedale di Circolo - Fondazione Macchi
Conditions:
Immunogenicity
Hematological Malignancies
Eligibility:
All Genders
18+ years
Brief Summary
Covid-19 is associated with a mortality rate of 33-37% in patients with hematological malignancies. At present, the anti-SARS-CoV-2 vaccination represents the most effective strategy for the preventi...
Detailed Description
Covid-19 is associated with a mortality rate of 33-37% in patients with hematological malignancies (Passamonti et al, 2020; Garcia-Suarez et al, 2020). Currently, there is little information on the se...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- History of hematological neoplasia (myeloid neoplasms, lymphoid neoplasms, plasma cell dyscrasias).
- Active hematological neoplasm.
Exclusion
- Hematological diseases, other than hematological malignancies.
Key Trial Info
Start Date :
April 13 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04878822
Start Date
April 13 2021
End Date
April 30 2023
Last Update
September 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UOC Ematologia, ASST Sette Laghi, Osp. Di Circolo e Fondazione Macchi
Varese, Lombardy, Italy, 21100